Missed our live webinar?

View our previous live webinars at a time that is convenient for you.

• January 9, 2021:  Updates from ASH 2020:  Promising Treatment Advances for MDS and AML @12 pm ET
  Speaker:  Amy Elizabeth DeZern, MD, MHS; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
  Updates from ASH 2020 will be presented. This webinar will provide an overview of new emerging treatments for MDS and AML patients. The latest promising clinical trials and research findings impacting the biology and treatment of MDS and AML patients will be discussed.
  View Webinar Q&A
• February 6, 2021: MDS:  Understanding Disease Characteristics and Progression @12 pm ET
  Speaker:  Azra Raza, MD; Columbia University Medical Center
  This webinar will provide an overview of MDS and how prognosis is determined, focusing on the MDS subtypes and disease progression. Understanding the diagnosis of MDS, details about the various approaches to treatment, and answers to common questions will be discussed.
  View Webinar
• March 13, 2021: MDS: Factors to Consider in the Initial Treatment Approach @12 pm ET
  Speaker:  Yazan Madanat, MD; University of Texas Southwestern Medical Center
  This webinar will provide an overview of MDS and what treatment path to take in a patient newly diagnosed with myelodysplastic syndromes.  Factors, such as:  the type of MDS; the prognostic score (risk score) of the MDS; a person’s age, overall health, and preferences will be discussed.
  View Webinar Q&A
• March 20, 2021: MDS & COVID-19 Vaccine Webinar @12 pm ET
  Peter T. Curtin, MD and Randy A. Taplitz, MD; City of Hope Medical Center
  This webinar will provide an overview of COVID-19 and myelodysplastic syndromes including frequently asked questions. The latest COVID-19 vaccines and what they mean for those with bone marrow failure disorders will be discussed.
  View Webinar
• April 17, 2021: Clinical Implications of Genetic Mutations in Myelodysplastic Syndromes @12 pm ET
  Rami Komrokji, MD; Moffitt Cancer Center
  This webinar will provide an overview of recent advances in the genetic understanding of MDS, with a particular focus on the emerging role for mutational data in clinical management as a potential tool to assist in diagnosis, risk stratification, and therapeutic decision-making.
  View Webinar
• May 8, 2021: Transfusion Dependence and Transfusion Support in MDS @12 pm ET
  Lewis R. Silverman, MD; Icahn School of Medicine at Mount Sinai
  This webinar will provide an overview of transfusion dependency in MDS, focusing on blood transfusion benefits and risks. Understanding the impact of transfusion dependence, and answers to common questions will be discussed.
  View Webinar
• June 5, 2021: Becoming a Partner in Your Care:  MDS Support Group @12 pm ET
  Sandra Kurtin, PhD, ANP-C, AOCN; The University of Arizona Cancer Center
  Join us for a free webinar to support our patients and loved ones.  This webinar will address all aspects of becoming a partner in your care.  We invite you to learn more about self-care, and the physical, social, and emotional challenges that patients and caregivers face.  Whether you are a patient or caregiver, you will be able to connect with others, gather ideas, learn about resources, and ask questions.
  View Webinar
• 17 de julio de 2021: Webcast de MDS en Español @12 pm hora del este
  Que son los sindromes mielodisplasicos?
  Guillermo Montalbán Bravo, MD, MD Anderson Cancer Center
  Este seminario les va a proveer como se determina el diagnóstico de MDS, se estará enfocando en los subtipos y la manifestación de MDS. Comprendiendo el diagnostico de MDS y los detalles de los diferentes tratamientos, y las respuestas a las preguntas más comunes serán desarrolladas.
  Avances en el tratamiento de los sindromes mielodisplasicos. 
  Guillermo Garcia-Manero, MD, MD Anderson Cancer Center
  Además, estaremos proveyendo los tratamientos y estrategias para los pacientes de MDS. Las últimas pruebas clínicas que son muy positivas y prometedor y el tratamiento y la biología de los pacientes con MDS que van a ser revisados.
  Moderado por Jessica MacIntyre, APRN, NP-C, AOCNP, Sylvester Comprehensive Cancer Center
  Este webinar se presentará en español.
  View Webinar
• August 7, 2021: Outcomes for High-Risk MDS Patients Undergoing Transplant vs Standard Non-Transplant Therapies @12 pm ET
  Erica D. Warlick, MD, University of Minnesota Medical Center
  This webinar will provide an overview of the role of allogeneic hematopoietic cell transplantation (alloHCT) for high-risk MDS patients. Standard therapies for patients with MDS including hypomethylating agents (HMAs) and a variety of novel agents outside of allogeneic HCT will be discussed.
  View Webinar
• 12 PM – 2 PM ET
  September 25, 2021 – Toronto MDS Patient Webinar
  Updates from EHA 2021: Promising Treatment Advances for MDS and AML – Heather Leitch, MD, St. Paul’s Hospital, Vancouver, Canada
  Updates from the European Hematology Association (EHA) 2021 Virtual Congress will be presented. This webinar will provide an overview of new emerging treatments for MDS and AML patients. The latest promising clinical trials and research findings impacting the biology and treatment of MDS, and AML patients will be discussed.The Role of Allogeneic Stem Cell Transplant in MDS – Bart L. Scott, MD, Fred Hutchinson Cancer Research Center, Seattle, Washington
  This presentation will focus on reduced-intensity allogeneic stem-cell transplantation as a treatment option for MDS and describe strategies to manage treatment side effects as well as potential long-term and late effects of hematopoietic cell transplantation.Aplastic Anemia and Myelodysplasia Association of Canada – Cindy Anthony, Executive Director, AAMAC
  About AAMAC and its resources for patients, caregivers and healthcare providers will be discussed.
  View Webinar
• October 16, 2021: CAR T Cell Therapy in MDS/AML @12 pm ET
  David A. Sallman, MD, Moffitt Cancer Center
  This webinar will provide an overview on CAR T cell immunotherapy, an approach that takes patients’ own immune cells and equips them with chimeric antigen receptors (CARs) that enhance their ability to target and eliminate cancer cells. Recent advances leading to next-generation CAR T therapies for MDS/AML patients will be discussed.
  View Webinar

Learn from experts about treatment therapies and strategies for Patients & Caregiver LIVING with MDS.

Thank you to Acceleron, Bristol-Myers Squibb, Gamida Cell, Jazz, Novartis, and Takeda for supporting these important events.